2.6(top 20%)
impact factor
802(top 20%)
papers
16.1K(top 10%)
citations
55(top 10%)
h-index
2.6(top 20%)
impact factor
950
all documents
17.1K
doc citations
87(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1Relationship between Oxidative Stress and Inflammatory Cytokines in Diabetic NephropathyCardiovascular Therapeutics2012505
2REVIEW: Plasminogen Activator Inhibitor‐1 (PAI‐1): A Key Factor Linking Fibrinolysis and Age‐Related Subclinical and Clinical ConditionsCardiovascular Therapeutics2010340
3Hypolipidemic, Antioxidant, and Antiinflammatory Activities of Microalgae SpirulinaCardiovascular Therapeutics2010313
4Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor AntagonistCardiovascular Therapeutics2009304
5The Novel Antioxidant Edaravone: From Bench to BedsideCardiovascular Therapeutics2008192
6Nutraceuticals and Atherosclerosis: Human TrialsCardiovascular Therapeutics2010185
7Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature ReviewCardiovascular Therapeutics2019183
8Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor BlockersCardiovascular Therapeutics2012138
9Natural Antioxidants and Hypertension: Promise and ChallengesCardiovascular Therapeutics2010137
10Xanthine Oxidase Inhibition For The Treatment Of Cardiovascular Disease: A Systematic Review and Meta‐AnalysisCardiovascular Therapeutics2012134
11The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fractionCardiovascular Therapeutics2018132
12Nutraceuticals in Diabetes and Metabolic SyndromeCardiovascular Therapeutics2010128
13REVIEW: Sodium Channel (Dys)Function and Cardiac ArrhythmiasCardiovascular Therapeutics2010128
14A Novel Hydrogen Sulfide Prodrug, SG1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure PatientsCardiovascular Therapeutics2015125
15Temporal and Spatial Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Following Myocardial InfarctionCardiovascular Therapeutics2012124
16In-Stent RestenosisCardiovascular Therapeutics2011120
17Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factor‐βCardiovascular Therapeutics2012112
18Liver X Receptors (LXR) as Therapeutic Targets in DyslipidemiaCardiovascular Therapeutics2008111
19Safety of Herbal Supplements: A Guide for CardiologistsCardiovascular Therapeutics2010111
20Dipeptidyl Peptidase‐4 Inhibitors and Cardiovascular Outcomes: Meta‐Analysis of Randomized Clinical Trials with 55,141 ParticipantsCardiovascular Therapeutics2014111
21Safety and Feasibility of Levosimendan Administration in Takotsubo Cardiomyopathy: A Case SeriesCardiovascular Therapeutics2013104
22The Cardiovascular Effects of GLP‐1 Receptor AgonistsCardiovascular Therapeutics2012102
23The Role of Homocysteine‐Lowering B‐Vitamins in the Primary Prevention of Cardiovascular DiseaseCardiovascular Therapeutics201497
24Serum Levels of Advanced Glycation End Products (AGEs) are Independent Correlates of Insulin Resistance in Nondiabetic SubjectsCardiovascular Therapeutics201296
25Myocardial Reverse RemodelingCardiovascular Therapeutics201291
26Assessment of Arterial Stiffness, A Translational Medicine Biomarker System for Evaluation of Vascular RiskCardiovascular Therapeutics200889
27Nutraceuticals and Prevention of Atherosclerosis: Focus on ω‐3 Polyunsaturated Fatty Acids and Mediterranean Diet PolyphenolsCardiovascular Therapeutics201089
28Nebivolol: A Highly Selective β1‐Adrenergic Receptor Blocker That Causes Vasodilation by Increasing Nitric OxideCardiovascular Therapeutics200888
29Adiponectin, an Unlocking AdipocytokineCardiovascular Therapeutics200988
30ARIES‐3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary HypertensionCardiovascular Therapeutics201285
31Erectile Dysfunction in High‐Risk Hypertensive Patients Treated with Beta‐Blockade AgentsCardiovascular Therapeutics201082
32Deficiency of a New Protein Associated with Cardiac Syndrome X; Called AdropinCardiovascular Therapeutics201381
33Ginsenoside Re: Pharmacological Effects on Cardiovascular SystemCardiovascular Therapeutics201280
34RESEARCH: Effects of Long‐Term Disease‐Modifying Antirheumatic Drugs on Endothelial Function in Patients with Early Rheumatoid ArthritisCardiovascular Therapeutics201079
35Cardio‐Selective Beta‐Blocker: Pharmacological Evidence and Their Influence on Exercise CapacityCardiovascular Therapeutics201379
36Drug-induced hERG Block and Long QT SyndromeCardiovascular Therapeutics201174
37Advanced Interatrial Block is Associated with Recurrence of Atrial Fibrillation Post Pharmacological CardioversionCardiovascular Therapeutics201473
38Antibiotic‐induced Cardiac ArrhythmiasCardiovascular Therapeutics201471
39Different Pharmacological Properties of Two Enantiomers in a Unique β-Blocker, NebivololCardiovascular Therapeutics200870
40Cilnidipine: A New Generation Ca2+ Channel Blocker with Inhibitory Action on Sympathetic Neurotransmitter ReleaseCardiovascular Therapeutics200970
41Benefits and Risks of Maintaining Normothermia during Cardiopulmonary Bypass in Adult Cardiac Surgery: A Systematic ReviewCardiovascular Therapeutics201169
42Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients with Atrial FibrillationCardiovascular Therapeutics201567
43Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection FractionCardiovascular Therapeutics201667
44STATIN-D Study: Comparison of the Influences of Rosuvastatin and Fluvastatin Treatment on the Levels of 25 Hydroxyvitamin DCardiovascular Therapeutics201166
45Role and Effective Therapeutic Target of Gut Microbiota in Heart FailureCardiovascular Therapeutics201965
46Soluble Epoxide Hydrolase Inhibitors and Heart FailureCardiovascular Therapeutics201163
47PI3K Inhibitors in Cardiovascular DiseaseCardiovascular Therapeutics201163
48GLP‐1 Receptor Agonists: Effects on Cardiovascular Risk ReductionCardiovascular Therapeutics201363
49Opportunity Nox: The Future of NADPH Oxidases as Therapeutic Targets in Cardiovascular DiseaseCardiovascular Therapeutics201363
50Stimulation of Reactive Oxygen Species and Collagen Synthesis by Angiotensin II in Cardiac FibroblastsCardiovascular Therapeutics201262